[{"orgOrder":0,"company":"23andMe","sponsor":"Almirall","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific Monoclonal Antibody","moa":"IL-36","graph1":"Dermatology","graph2":"Preclinical","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"23andMe \/ Almirall, S.A","highestDevelopmentStatusID":"4","companyTruncated":"23andMe \/ Almirall, S.A"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Large molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Staphylococcus epidermidis strain","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Antimicrobial therapy","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"WEG232","moa":"Substance P receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable "},{"orgOrder":0,"company":"Isoprene Pharmaceuticals","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Retinamide","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Isoprene Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Isoprene Pharmaceuticals \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Isoprene Pharmaceuticals \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Retinamide","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Chelexa Biosciences","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antimicrobial therapy","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Chelexa Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Chelexa Biosciences \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Chelexa Biosciences \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VNLG 152","moa":"Retinoic acid metabolism","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"IRAK4","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"George Washington University","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"WEG232","moa":"Substance P receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ George Washington University","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ George Washington University"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"$150.0 million","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"IRAK4","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":2.1499999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":2.1499999999999999,"dosageForm":"","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Isoprene Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"VNLG 152","moa":"Retinoic acid metabolism","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Isoprene Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Isoprene Pharmaceuticals"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Antibiotic","moa":"Staphylococcal biofilm formation","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"HT-003","moa":"TLR2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Azitra","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"October 2020","year":"2020","type":"Series B Financing","leadProduct":"ATR-01","moa":"Filaggrin","graph1":"Dermatology","graph2":"Preclinical","graph3":"Azitra","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Topical","sponsorNew":"Azitra \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Azitra \/ Leaps by Bayer"},{"orgOrder":0,"company":"Molteni Farmaceutici","sponsor":"Titan Pharmaceuticals Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Peptide","date":"November 2020","year":"2020","type":"Public Offering","leadProduct":"JT-09","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Molteni Farmaceutici","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Molteni Farmaceutici \/ Titan Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Molteni Farmaceutici \/ Titan Pharma"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","date":"November 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Calcitonin gene-related peptide receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Disintegrating Tablet","sponsorNew":"Weill Cornell Medicine \/ Biohaven Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Weill Cornell Medicine \/ Biohaven Pharmaceutical"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"HT-001","moa":"EGFR","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Evommune","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"IRAK4","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Eli Lilly \/ Evommune","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Evommune"},{"orgOrder":0,"company":"DICE Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"IL-17A","graph1":"Dermatology","graph2":"Preclinical","graph3":"DICE Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"DICE Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"DICE Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"HT-001","moa":"EGFR","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Charles River Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Charles River Laboratories"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cannassure Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Cannassure","highestDevelopmentStatusID":"4","companyTruncated":"Lipidor AB \/ Cannassure"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"January 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"HT-003","moa":"TLR2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Weill Cornell Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Weill Cornell Medicine \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Peptide","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"JT-09","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Titan Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Titan Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"HT-001","moa":"EGFR","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Camargo Pharmaceutical","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","date":"February 2021","year":"2021","type":"Partnership","leadProduct":"HT-001","moa":"EGFR","graph1":"Dermatology","graph2":"Preclinical","graph3":"Camargo Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Camargo Pharmaceutical \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Camargo Pharmaceutical \/ Hoth Therapeutics"},{"orgOrder":0,"company":"UC San Diego","sponsor":"MatriSys Bioscience","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"MSB-3163","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"UC San Diego","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"UC San Diego \/ MatriSys Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"UC San Diego \/ MatriSys Bioscience"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"PXS-6302","moa":"Pan-LOX","graph1":"Dermatology","graph2":"Preclinical","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"Pharmaxis \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pharmaxis \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"HT-001","moa":"EGFR","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Cell and Gene therapy","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Purion Processed Dehydrated Human Amnion\/Chorion Membrane","moa":"TGF beta1","graph1":"Dermatology","graph2":"Preclinical","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MiMedx \/ Not Applicable"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Stemson Therapeutics","sponsor":"Genoa Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Cell and Gene therapy","date":"July 2021","year":"2021","type":"Series A Financing","leadProduct":"Human Induced Pluripotent Stem Cells","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Stemson Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"","sponsorNew":"Stemson Therapeutics \/ Genoa Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Stemson Therapeutics \/ Genoa Ventures"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Nrf2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"MUSC Foundation for Research Development","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Peptide","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"TP-2021","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ MUSC Foundation for Research Development","highestDevelopmentStatusID":"4","companyTruncated":"Titan Pharmaceuticals Inc \/ MUSC Foundation for Research Development"},{"orgOrder":0,"company":"BiomX","sponsor":"Maruho","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"October 2021","year":"2021","type":"Agreement","leadProduct":"BX005","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Maruho Co. Ltd.","highestDevelopmentStatusID":"4","companyTruncated":"BiomX \/ Maruho Co. Ltd."},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Cannassure Therapeutics","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"October 2021","year":"2021","type":"Expanded Collaboration","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Cannassure Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lipidor AB \/ Cannassure Therapeutics"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"OLX104C","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Votucalis","moa":"H1\/H2\/H3\/H4","graph1":"Dermatology","graph2":"Preclinical","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"DispersinB","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Marc Edwards","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"May 2022","year":"2022","type":"Private Placement","leadProduct":"DispersinB","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Marc Edwards","highestDevelopmentStatusID":"4","companyTruncated":"Kane Biotech \/ Marc Edwards"},{"orgOrder":0,"company":"C4X Discovery","sponsor":"Sanofi","pharmaFlowCategory":"D","upfrontCash":"$7.3 million","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"IL-17A","graph1":"Dermatology","graph2":"Preclinical","graph3":"C4X Discovery","amount2":0.42999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"C4X Discovery \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"C4X Discovery \/ Sanofi"},{"orgOrder":0,"company":"WuXi AppTec","sponsor":"Sirona Biochem Corp","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"June 2022","year":"2022","type":"Agreement","leadProduct":"TFC-1326","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"WuXi AppTec","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"WuXi AppTec \/ Sirona Biochem","highestDevelopmentStatusID":"4","companyTruncated":"WuXi AppTec \/ Sirona Biochem"},{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","upfrontCash":"$16.0 million","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"DS-234","moa":"CD200 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ducentis BioTherapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Ducentis BioTherapeutics \/ Arcutis","highestDevelopmentStatusID":"4","companyTruncated":"Ducentis BioTherapeutics \/ Arcutis"},{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","upfrontCash":"$16.0 million","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"September 2022","year":"2022","type":"Acquisition","leadProduct":"DS-234","moa":"CD200 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ducentis BioTherapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ducentis BioTherapeutics \/ Arcutis Biotherapeutics"},{"orgOrder":0,"company":"Kamari Pharma","sponsor":"GIBF2","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"TRPV3","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kamari Pharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Kamari Pharma \/ GIBF2","highestDevelopmentStatusID":"4","companyTruncated":"Kamari Pharma \/ GIBF2"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Crisaborole","moa":"Nrf2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aditxt","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"ADI-100","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Aditxt \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ Not Applicable"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Yale University","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","date":"November 2022","year":"2022","type":"Licensing Agreement","leadProduct":"TLC-1235","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"OrsoBio \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"OrsoBio \/ Yale University"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"TFC-1326","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Sirona Biochem Corp \/ Not Applicable"},{"orgOrder":0,"company":"OliX Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"OLX104C","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"OliX Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"OliX Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"OliX Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Dutasteride","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yuyu Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Yuyu Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","upfrontCash":"$45.0 million","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"December 2022","year":"2022","type":"Termination","leadProduct":"SNA-based Therapeutic","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Exicure","amount2":1.05,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":1.05,"dosageForm":"","sponsorNew":"Exicure \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Exicure \/ AbbVie"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aldena Therapeutics","sponsor":"Medicxi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","date":"March 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Aldena Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Aldena Therapeutics \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Aldena Therapeutics \/ Medicxi"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Rubedo Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Rubedo Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Alpaca-derived Nanosized Antibody","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Astria Therapeutics","pharmaFlowCategory":"D","upfrontCash":"$15.0 million","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"STAR-0310","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Ichnos Sciences","amount2":0.32000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.32000000000000001,"dosageForm":"","sponsorNew":"Ichnos Sciences \/ Astria Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Ichnos Sciences \/ Astria Therapeutics"},{"orgOrder":0,"company":"Triveni Bio","sponsor":"Atlas Venture","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"October 2023","year":"2023","type":"Series A Financing","leadProduct":"TRIV-509","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Triveni Bio","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Triveni Bio \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"Triveni Bio \/ Atlas Venture"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","date":"November 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Derm-Biome Pharmaceuticals \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Sanofi Ventures","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Cell and Gene therapy","date":"December 2023","year":"2023","type":"Series B Financing","leadProduct":"EB005","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Eligo Bioscience \/ Sanofi Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bioscience \/ Sanofi Ventures"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Licensing Agreement","leadProduct":"BD9","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Biolojic Design \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic Design \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Stemson Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Cell and Gene therapy","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Stemson Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Stemson Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Stemson Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Medicxi","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Financing","leadProduct":"siRNA Lipid Conjugate-based Therapy","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Alys Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Gel","sponsorNew":"Alys Pharmaceuticals \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Alys Pharmaceuticals \/ Medicxi"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Almirall","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"NN-8828","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Almirall","highestDevelopmentStatusID":"4","companyTruncated":"Novo Nordisk \/ Almirall"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"DB-007-4","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Derm-Biome Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Scinai Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Scinai Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Derm-Biome Pharmaceuticals","sponsor":"Natural Sciences and Engineering Council","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Funding","leadProduct":"DB-007-4","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Derm-Biome Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Derm-Biome Pharmaceuticals \/ Natural Sciences and Engineering Council","highestDevelopmentStatusID":"4","companyTruncated":"Derm-Biome Pharmaceuticals \/ Natural Sciences and Engineering Council"},{"orgOrder":0,"company":"Proteologix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","upfrontCash":"$850.0 million","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","date":"May 2024","year":"2024","type":"Acquisition","leadProduct":"PX128","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Proteologix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.84999999999999998,"dosageForm":"","sponsorNew":"Proteologix \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Proteologix \/ Johnson & Johnson"},{"orgOrder":0,"company":"Proteologix","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","upfrontCash":"$850.0 million","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"PX128","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Proteologix","amount2":0.84999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.84999999999999998,"dosageForm":"","sponsorNew":"Proteologix \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Proteologix \/ Johnson & Johnson"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"MC2-32","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"MC2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MC2 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lindus Health","sponsor":"Acinonyx Bio","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Undisclosed","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"ACX","moa":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lindus Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Lindus Health \/ Acinonyx Bio","highestDevelopmentStatusID":"4","companyTruncated":"Lindus Health \/ Acinonyx Bio"}]
Find Novel Dermatology Drugs in Preclinical Development
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
